This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Larry Green, PhD
CEO at Ablexis


Larry Green is founder and CEO of Ablexis and AlivaMab Biologics. He brings over thirty years of experience in the development and use of transgenic mice for the discovery of human therapeutic antibodies, contributing to the discovery of nine approved antibody drugs to date. He is an inventor on more than 80 issued patents covering antibody technologies and therapeutic product candidates, including the XenoMouse® technology, in use today at Amgen after the acquisition of Abgenix in 2006. He founded Ablexis in 2009, where he led the design and creation of the AlivaMab® Mouse, which has now grown into a suite of nine (and counting) different transgenic mouse strains optimized for antibody drug discovery and development. Larry received his Ph.D. from the University of Wisconsin-Madison.

Agenda Sessions

  • Celebrating Diversity: AlivaMab® Discovery and Engineering Platforms for Novel Biologic Therapeutics